Ftse Mib
33.666,50
1,07%
DAX
18.276,83
0,50%
S&P 500
5.463,40
-0,02%
NASDAQ
17.656,83
-0,18%
Bitcoin
61.359,23
-2,86%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Protagonist Therapeutics Inc (PTGX) Protagonist Therapeutics Inc (PTGX) Notizie

PTGX

Protagonist Therapeutics (PTGX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PTGX
DataOraFonteTitoloSimboloCompagnia
11/06/202422:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PTGXProtagonist Therapeutics Inc
07/06/202422:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PTGXProtagonist Therapeutics Inc
07/05/202422:51Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PTGXProtagonist Therapeutics Inc
07/05/202422:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PTGXProtagonist Therapeutics Inc
16/04/202415:00GlobeNewswire Inc.Turnstone Biologics Appoints William Waddill to its Board of DirectorsNASDAQ:PTGXProtagonist Therapeutics Inc
14/02/202413:47Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PTGXProtagonist Therapeutics Inc
18/12/202322:15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PTGXProtagonist Therapeutics Inc
11/08/202322:32Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PTGXProtagonist Therapeutics Inc
12/05/202313:00PR Newswire (US)Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113NASDAQ:PTGXProtagonist Therapeutics Inc
11/05/202322:05PR Newswire (US)Protagonist Therapeutics to Participate in the JMP Securities Life Sciences ConferenceNASDAQ:PTGXProtagonist Therapeutics Inc
11/05/202316:17PR Newswire (US)Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology AssociationNASDAQ:PTGXProtagonist Therapeutics Inc
04/05/202322:39Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTGXProtagonist Therapeutics Inc
04/05/202322:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTGXProtagonist Therapeutics Inc
04/05/202322:05PR Newswire (US)Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:PTGXProtagonist Therapeutics Inc
19/04/202322:29Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTGXProtagonist Therapeutics Inc
12/04/202323:17Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:PTGXProtagonist Therapeutics Inc
06/04/202312:02Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PTGXProtagonist Therapeutics Inc
15/03/202322:02Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PTGXProtagonist Therapeutics Inc
15/03/202321:52Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PTGXProtagonist Therapeutics Inc
08/03/202308:05Dow Jones NewsProtagonist Therapeutics Sees Positive Topline Results in JNJ-2113 TrialNASDAQ:PTGXProtagonist Therapeutics Inc
07/03/202314:00PR Newswire (US)Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in PsoriasisNASDAQ:PTGXProtagonist Therapeutics Inc
14/02/202322:25Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTGXProtagonist Therapeutics Inc
09/02/202317:45Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PTGXProtagonist Therapeutics Inc
21/12/202222:05PR Newswire (US)Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:PTGXProtagonist Therapeutics Inc
01/12/202213:05PR Newswire (US)Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology SummitNASDAQ:PTGXProtagonist Therapeutics Inc
18/11/202200:21Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTGXProtagonist Therapeutics Inc
16/11/202222:05PR Newswire (US)Protagonist Therapeutics Reports Granting of Inducement AwardNASDAQ:PTGXProtagonist Therapeutics Inc
14/11/202205:10TipRanksAnalysts Are Bullish on Top Healthcare Stocks: Passage Bio (PASG), Privia Health Group (PRVA)NASDAQ:PTGXProtagonist Therapeutics Inc
09/11/202222:15TipRanksJMP Securities Remains a Buy on Protagonist Therapeutics (PTGX)NASDAQ:PTGXProtagonist Therapeutics Inc
08/11/202222:05PR Newswire (US)Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:PTGXProtagonist Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PTGX

La tua Cronologia

TG
AXJ
Equitable
TSX
VLNS
The Valens
TG
6I4
Zaptec ASA
BOV
BRFSG240
BRFSG240 Ex:24
BIT
P1W3Q5
NLBNPIT1W3Q5 20991231 94...
BIT
P20JA2
NLBNPIT20JA2 20991231 16...
LSE
IVS
Inveresk
EU
P747S
P747S
CREX
FIROBTC
Firo
BOV
A1YX34R
Alteryx
CREX
DLXBTC
Diplex Coin
ASX
WBCHBC
Westpac Banking
COIN
CAPYYETH
Capy
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network